Literature DB >> 16087686

Ribosomal frameshifting on MJD-1 transcripts with long CAG tracts.

André Toulouse1, Faith Au-Yeung, Claudia Gaspar, Julie Roussel, Patrick Dion, Guy A Rouleau.   

Abstract

The expanded CAG tract diseases are a heterogeneous group of late-onset neurodegenerative disorders characterized by the accumulation of insoluble protein material and premature neuronal cell death. Recent work has provided support for several mechanisms that may account for neurodegeneration, but no unifying mechanism has emerged. We have previously demonstrated that in SCA3, the expanded CAG tract in the MJD-1 transcript is prone to frameshifting, which may lead to the production of polyalanine-containing proteins. To further examine the occurrence of frameshifting and understand its mechanism and possible role in pathogenesis, a cellular model was established. We show that this phenomenon results from ribosomal slippage to the -1 frame exclusively, that ribosomal frameshifting depends on the presence of long CAG tracts and that polyalanine-frameshifted proteins may enhance polyglutamine-associated toxicity, possibly contributing to pathogenesis. Finally, we present evidence that anisomycin, a ribosome-interacting drug that reduces -1 frameshifting, also reduces toxicity, suggesting a new therapeutic opportunity for these disorders.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16087686     DOI: 10.1093/hmg/ddi299

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  33 in total

Review 1.  Augmented genetic decoding: global, local and temporal alterations of decoding processes and codon meaning.

Authors:  Pavel V Baranov; John F Atkins; Martina M Yordanova
Journal:  Nat Rev Genet       Date:  2015-08-11       Impact factor: 53.242

2.  Polyalanine and polyserine frameshift products in Huntington's disease.

Authors:  J E Davies; D C Rubinsztein
Journal:  J Med Genet       Date:  2006-06-26       Impact factor: 6.318

Review 3.  New pathologic mechanisms in nucleotide repeat expansion disorders.

Authors:  C M Rodriguez; P K Todd
Journal:  Neurobiol Dis       Date:  2019-06-21       Impact factor: 5.996

Review 4.  Comparative genomics and molecular dynamics of DNA repeats in eukaryotes.

Authors:  Guy-Franck Richard; Alix Kerrest; Bernard Dujon
Journal:  Microbiol Mol Biol Rev       Date:  2008-12       Impact factor: 11.056

Review 5.  A gripping tale of ribosomal frameshifting: extragenic suppressors of frameshift mutations spotlight P-site realignment.

Authors:  John F Atkins; Glenn R Björk
Journal:  Microbiol Mol Biol Rev       Date:  2009-03       Impact factor: 11.056

Review 6.  Machado-Joseph disease/spinocerebellar ataxia type 3.

Authors:  Henry Paulson
Journal:  Handb Clin Neurol       Date:  2012

Review 7.  The expanding biology of the C9orf72 nucleotide repeat expansion in neurodegenerative disease.

Authors:  Aaron R Haeusler; Christopher J Donnelly; Jeffrey D Rothstein
Journal:  Nat Rev Neurosci       Date:  2016-05-06       Impact factor: 34.870

Review 8.  Ribosomal frameshifting and transcriptional slippage: From genetic steganography and cryptography to adventitious use.

Authors:  John F Atkins; Gary Loughran; Pramod R Bhatt; Andrew E Firth; Pavel V Baranov
Journal:  Nucleic Acids Res       Date:  2016-07-19       Impact factor: 16.971

9.  Increased transcript diversity: novel splicing variants of Machado-Joseph disease gene (ATXN3).

Authors:  Conceição Bettencourt; Cristina Santos; Rafael Montiel; Maria do Carmo Costa; Pablo Cruz-Morales; Liliana Ribeiro Santos; Nelson Simões; Teresa Kay; João Vasconcelos; Patrícia Maciel; Manuela Lima
Journal:  Neurogenetics       Date:  2009-08-28       Impact factor: 2.660

10.  RAN Translation in Huntington Disease.

Authors:  Monica Bañez-Coronel; Fatma Ayhan; Alex D Tarabochia; Tao Zu; Barbara A Perez; Solaleh Khoramian Tusi; Olga Pletnikova; David R Borchelt; Christopher A Ross; Russell L Margolis; Anthony T Yachnis; Juan C Troncoso; Laura P W Ranum
Journal:  Neuron       Date:  2015-11-18       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.